Cargando…
An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis
Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662105/ https://www.ncbi.nlm.nih.gov/pubmed/33207859 http://dx.doi.org/10.4081/ejh.2020.3155 |
_version_ | 1783609329527554048 |
---|---|
author | Li, Ziqi Hong, Zhinan Zheng, Yuesheng Dong, Yongwei He, Wei Yuan, Yingjia Guo, Junbiao |
author_facet | Li, Ziqi Hong, Zhinan Zheng, Yuesheng Dong, Yongwei He, Wei Yuan, Yingjia Guo, Junbiao |
author_sort | Li, Ziqi |
collection | PubMed |
description | Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention. |
format | Online Article Text |
id | pubmed-7662105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-76621052020-11-17 An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis Li, Ziqi Hong, Zhinan Zheng, Yuesheng Dong, Yongwei He, Wei Yuan, Yingjia Guo, Junbiao Eur J Histochem Article Osteoporosis (OP) is a complex systemic disease characterized by a loss of bone density, leading to bone fragility and an increase risk of fractures of the hip, spine and wrist. The clinical therapeutic effect is still far from satisfactory. Thus, further studies are urgently needed to explore the pathogenesis of OP. In this study, our aim is to explore the underlying molecular mechanism of lncRNA H19/miR-29a-3p axis for regulating of inflammation, proliferation and apoptosis in OP. The expression of lncRNA H19 was significantly upregulated in OP samples compared with the health control. Subsequently, we found that miR-29a-3p is the target of lncRNA H19 in OP. Furthermore, the knockdown of lncRNA H19 was validated to promote the expression of pro-inflammatory mediators, repress cell proliferation and inhibit cell apoptosis in vitro. Moreover, the modulating effects of lncRNA-H19 on the expressions of pro-inflammatory mediators, cell proliferation and apoptosis in vitro were diminished after co-transfecting with miR-29a-3p inhibitor and siRNA-H19. Thus, we concluded that lncRNA H19/miR-29a-3p axis was involved in the development of OP. This study might provide a better understanding of OP development and a potential therapeutic target for OP intervention. PAGEPress Publications, Pavia, Italy 2020-11-06 /pmc/articles/PMC7662105/ /pubmed/33207859 http://dx.doi.org/10.4081/ejh.2020.3155 Text en ©Copyright: the Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Li, Ziqi Hong, Zhinan Zheng, Yuesheng Dong, Yongwei He, Wei Yuan, Yingjia Guo, Junbiao An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title | An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_full | An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_fullStr | An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_full_unstemmed | An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_short | An emerging potential therapeutic target for osteoporosis: LncRNA H19/miR-29a-3p axis |
title_sort | emerging potential therapeutic target for osteoporosis: lncrna h19/mir-29a-3p axis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662105/ https://www.ncbi.nlm.nih.gov/pubmed/33207859 http://dx.doi.org/10.4081/ejh.2020.3155 |
work_keys_str_mv | AT liziqi anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT hongzhinan anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT zhengyuesheng anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT dongyongwei anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT hewei anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yuanyingjia anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT guojunbiao anemergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT liziqi emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT hongzhinan emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT zhengyuesheng emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT dongyongwei emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT hewei emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT yuanyingjia emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis AT guojunbiao emergingpotentialtherapeutictargetforosteoporosislncrnah19mir29a3paxis |